Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Boehringer Ingelheim Pharmaceuticals, Inc. is seeking a Director, Early Value Lead (eVL) to shape US Early Value Strategy across therapeutic areas.
You will lead pricing research, market access assessments, and optimized launch sequencing to maximize price, reimbursement, and profitability.
The base salary range for this position is $230,400 to $345,600. The position may be eligible for a role specific discretionary bonus, relocation, and/or other compensation elements. We continuously review market data and may adjust salary ranges as needed in the future. Actual compensation will be based on job-related factors such as skills, experience, and qualifications, and other factors permitted by law. For an overview of our benefits please click here .
As an employee of Boehringer Ingelheim, you will actively contribute to the discovery, development, and delivery of our products to our patients and customers. Our global presence provides opportunity for all employees to collaborate internationally, offering visibility and opportunity to directly contribute to the companies' success. We realize that our strength and competitive advantage lie with our people. We support our employees in several ways to foster a healthy working environment, meaningful work, mobility, networking, and work-life balance. Our competitive compensation and benefit programs reflect Boehringer Ingelheim's high regard for our employees.
This role is based on-site at our Ridgefield, CT location with hybrid flexibility of 2-3 days per week on-site.
The Director, Early Value Lead (eVL) is responsible for making key strategic decisions for the development of the US Early Value Strategy for assigned therapeutic areas.
The eVL will create asset or indication-specific US Early Value Strategies that maximize price & reimbursement, market share, sales, and profitability. The eVL will do this by executing pricing research, market access assessments, defining optimized launch sequencing and co-development of payor value propositions that illustrate the value of the product.
The role will require leadership to ensure Value perspectives from the US market are incorporated into deliverables such as the Asset Evidence Plan, Target Product Profile (TPP) and Integrated Asset Plan (IAP) and that those perspectives brought forward to corporate colleagues then drive co-creation of the early asset development strategy with the Global Asset Team.
They will be responsible for collaborating with multiple functional groups as part of their knowledge network, including but not limited to Marketing, Medical, Clinical Development, HEOR, Regulatory, Finance, Competitive Intelligence, Forecasting, Analytics, and Insights, Legal, Public Policy and Global Market Access teams, to define and execute on asset team strategic and operational deliverables.
Additionally, the eVL is responsible for development and ongoing assessment of the overall Gross to Net pricing strategy for assets across one or more therapeutic areas in the US, across all channels beginning before Phase I via indication assessments through launch of an asset. This includes setting of WAC price and corresponding discounting/rebating strategies to estimate net price for forecasting.